Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyJesús G. Berdeja, Sundar Jagannath, Saad Z. Usmani et al.|The Lancet|2021Cited by 1.7k
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpThomas G. Martin, Sundar Jagannath, Saad Z. Usmani et al.|Journal of Clinical Oncology|2022Cited by 647
Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaPaul G. Richardson, Irene M. Ghobrial, Susanna Jacobus et al.|New England Journal of Medicine|2022Cited by 457
CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.Yi Lin, Sundar Jagannath, Thomas Martin et al.|Journal of Clinical Oncology|2023Cited by 117
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple MyelomaSundar Jagannath, Peter M. Voorhees, Thomas G. Martin et al.|Journal of Clinical Oncology|2025Cited by 107